{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:50:21Z","timestamp":1790718621678,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11912-022-01285-1","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T05:02:51Z","timestamp":1649653371000},"page":"1133-1143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances"],"prefix":"10.1007","volume":"24","author":[{"given":"J\u00e9r\u00f4me","family":"Paillassa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-9992","authenticated-orcid":false,"given":"Xavier","family":"Troussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"1285_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"key":"1285_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-020-0328-z","volume":"10","author":"J Paillassa","year":"2020","unstructured":"Paillassa J, Cornet E, Noel S, Tomowiak C, Lepretre S, Vaudaux S, et al. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020;10:62. https:\/\/doi.org\/10.1038\/s41408-020-0328-z.","journal-title":"Blood Cancer J"},{"key":"1285_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/ccr3.1635","volume":"6","author":"E Durot","year":"2018","unstructured":"Durot E, Quinquenel A, Kleiber JC, Patey M, Bazin A, Delmer A. Skeletal involvement of hairy cell leukemia. Clin Case Rep. 2018;6:1651\u20132. https:\/\/doi.org\/10.1002\/ccr3.1635.","journal-title":"Clin Case Rep"},{"key":"1285_CR4","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1016\/S1470-2045(18)30609-0","volume":"20","author":"L Notarfranchi","year":"2019","unstructured":"Notarfranchi L, Russo F, Re F, Mancini C, Martella E, Falini B, et al. Hairy cell leukaemia mimicking multiple myeloma. Lancet Oncol. 2019;20:e187. https:\/\/doi.org\/10.1016\/S1470-2045(18)30609-0.","journal-title":"Lancet Oncol"},{"key":"1285_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.beha.2015.10.020","volume":"28","author":"T Tadmor","year":"2015","unstructured":"Tadmor T, Polliack A. Hairy cell leukemia: Uncommon clinical features, unusual sites of involvement and some rare associations. Best Pract Res Clin Haematol. 2015;28:193\u20139. https:\/\/doi.org\/10.1016\/j.beha.2015.10.020.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1285_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1185\/03007995.2014.971358","volume":"31","author":"CA Dasanu","year":"2015","unstructured":"Dasanu CA, Van den Bergh M, Pepito D, Alvarez AJ. Autoimmune disorders in patients with hairy cell leukemia: are they more common than previously thought? Curr Med Res Opin. 2015;31:17\u201323. https:\/\/doi.org\/10.1185\/03007995.2014.971358.","journal-title":"Curr Med Res Opin"},{"key":"1285_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1756-8722-3-35","volume":"3","author":"LA Anderson","year":"2010","unstructured":"Anderson LA, Engels EA. Autoimmune conditions and hairy cell leukemia: an exploratory case-control study. J Hematol Oncol. 2010;3:35. https:\/\/doi.org\/10.1186\/1756-8722-3-35.","journal-title":"J Hematol Oncol"},{"key":"1285_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443\u201359. https:\/\/doi.org\/10.3322\/caac.21357.","journal-title":"CA Cancer J Clin"},{"key":"1285_CR9","unstructured":"Le Guyader-Peyrou S, Defossez G, Dantony E, Mounier M, Cornet E, Uhry Z, et al. Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. Etude \u00e0 partir des registres des cancers du r\u00e9seau Francim. Volume 2\u202f: H\u00e9mopathies malignes. INCA. 2019."},{"key":"1285_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/10428190290021560","volume":"43","author":"L Hardell","year":"2002","unstructured":"Hardell L, Eriksson M, Nordstrom M. Exposure to pesticides as risk factor for non-Hodgkin\u2019s lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies. Leuk Lymphoma. 2002;43:1043\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1285_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","volume":"2014","author":"JR Cerhan","year":"2014","unstructured":"Cerhan JR, Kricker A, Paltiel O, Flowers CR, Wang SS, Monnereau A, et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the interlymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:15\u201325. https:\/\/doi.org\/10.1093\/jncimonographs\/lgu010.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1285_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5271\/sjweh.143","volume":"22","author":"J Clavel","year":"1996","unstructured":"Clavel J, H\u00e9mon D, Mandereau L, Delemotte B, S\u00e9verin F, Flandrin G. Farming, pesticide use and hairy-cell leukemia. Scand J Work Environ Health. 1996;22:285\u201393.","journal-title":"Scand J Work Environ Health"},{"key":"1285_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3109\/10428194.2011.610011","volume":"52","author":"C Aristeguieta","year":"2011","unstructured":"Aristeguieta C, de Perio MA. Three cases of hairy cell leukemia in coal miners. Leuk Lymphoma. 2011;52:2391\u20132. https:\/\/doi.org\/10.3109\/10428194.2011.610011.","journal-title":"Leuk Lymphoma"},{"key":"1285_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2141.1995.tb05261.x","volume":"91","author":"J Clavel","year":"1995","unstructured":"Clavel J, Mandereau L, Cordier S, Le Goaster C, H\u00e9mon D, Conso F, et al. Hairy cell leukaemia, occupation, and smoking. Br J Haematol. 1995;91:154\u201361.","journal-title":"Br J Haematol"},{"key":"1285_CR15","first-page":"57","volume":"14 Suppl 1","author":"E Matutes","year":"1994","unstructured":"Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14 Suppl 1:57\u201361.","journal-title":"Leuk Lymphoma"},{"key":"1285_CR16","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1158\/0008-5472.CAN-15-0893","volume":"75","author":"N Poret","year":"2015","unstructured":"Poret N, Fu Q, Guihard S, Cheok M, Miller K, Zeng G, et al. CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy. Cancer Res. 2015;75:3902\u201311. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0893.","journal-title":"Cancer Res"},{"key":"1285_CR17","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF Mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1014209.","journal-title":"N Engl J Med"},{"key":"1285_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/jnci\/djk030","volume":"99","author":"M Hisada","year":"2007","unstructured":"Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst. 2007;99:215\u201322. https:\/\/doi.org\/10.1093\/jnci\/djk030.","journal-title":"J Natl Cancer Inst"},{"key":"1285_CR19","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.V83.10.2931.2931","volume":"83","author":"P Kampmeier","year":"1994","unstructured":"Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman JW. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood. 1994;83:2931\u20138.","journal-title":"Blood"},{"key":"1285_CR20","doi-asserted-by":"crossref","unstructured":"Angelova EA, Medeiros LJ, Wang W, Muzzafar T, Lu X, Khoury JD, et al. Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Modern Patho. 2018.31(11):1717\u201332.","DOI":"10.1038\/s41379-018-0093-8"},{"key":"1285_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ng.2828","volume":"46","author":"JJ Waterfall","year":"2014","unstructured":"Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46:8\u201310. https:\/\/doi.org\/10.1038\/ng.2828.","journal-title":"Nat Genet"},{"key":"1285_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/10428194.2016.1185786","volume":"58","author":"EF Mason","year":"2017","unstructured":"Mason EF, Brown RD, Szeto DP, Gibson CJ, Jia Y, Garcia EP, et al. Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leuk Lymphoma. 2017;58:233\u20136. https:\/\/doi.org\/10.1080\/10428194.2016.1185786.","journal-title":"Leuk Lymphoma"},{"key":"1285_CR23","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","volume":"114","author":"F Forconi","year":"2009","unstructured":"Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood. 2009;114:4696\u2013702. https:\/\/doi.org\/10.1182\/blood-2009-03-212449.","journal-title":"Blood"},{"key":"1285_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2141.2012.09163.x","volume":"158","author":"SL Hockley","year":"2012","unstructured":"Hockley SL, Else M, Morilla A, Wotherspoon A, Dearden C, Catovsky D, et al. The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol. 2012;158:347\u201354. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09163.x.","journal-title":"Br J Haematol"},{"key":"1285_CR25","doi-asserted-by":"publisher","first-page":"blood-2017-01-7","DOI":"10.1182\/blood-2017-01-765107","volume":"130","author":"BH Durham","year":"2017","unstructured":"Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, et al. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017;130:blood-2017-01-765107. https:\/\/doi.org\/10.1182\/blood-2017-01-765107.","journal-title":"Blood"},{"key":"1285_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.beha.2015.09.002","volume":"28","author":"E Matutes","year":"2015","unstructured":"Matutes E, Mart\u00ednez-Trillos A, Campo E. Hairy cell leukaemia-variant: disease features and treatment. Best Pract Res Clin Haematol. 2015;28:253\u201363. https:\/\/doi.org\/10.1016\/j.beha.2015.09.002.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1285_CR27","first-page":"253","volume":"13","author":"A Traverse-Glehen","year":"2012","unstructured":"Traverse-Glehen A, Baseggio L, Salles G, Coiffier B, Felman P, Berger F. Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. Discov Med. 2012;13:253\u201365.","journal-title":"Discov Med"},{"key":"1285_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hon.957","volume":"29","author":"L Baseggio","year":"2011","unstructured":"Baseggio L, Traverse-Glehen A, Callet-Bauchu E, Morel D, Magaud JP, Berger F, et al. Relevance of a scoring system including CD11c expression in the identification of splenic diffuse red pulp small B-cell lymphoma (SRPL). Hematol Oncol. 2011;29:47\u201351. https:\/\/doi.org\/10.1002\/hon.957.","journal-title":"Hematol Oncol"},{"key":"1285_CR29","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1111\/ijlh.12824","volume":"40","author":"R Favre","year":"2018","unstructured":"Favre R, Manzoni D, Traverse-Glehen A, Verney A, Jallades L, Callet-Bauchu E, et al. Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. Int J Lab Hematol. 2018;40:e59-62. https:\/\/doi.org\/10.1111\/ijlh.12824.","journal-title":"Int J Lab Hematol"},{"key":"1285_CR30","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2016-11-751024","volume":"129","author":"S Curiel-Olmo","year":"2017","unstructured":"Curiel-Olmo S, Mond\u00e9jar R, Almaraz C, Mollejo M, Cereceda L, Mar\u00e8s R, et al. Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. Blood. 2017;129:1042\u20135. https:\/\/doi.org\/10.1182\/blood-2016-11-751024.","journal-title":"Blood"},{"key":"1285_CR31","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3324\/haematol.2016.160192","volume":"102","author":"L Jallades","year":"2017","unstructured":"Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, et al. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica. 2017;102:1758\u201366. https:\/\/doi.org\/10.3324\/haematol.2016.160192.","journal-title":"Haematologica"},{"key":"1285_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/bjh.12735","volume":"165","author":"S Tschernitz","year":"2014","unstructured":"Tschernitz S, Flossbach L, Bonengel M, Roth S, Rosenwald A, Geissinger E. Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. Br J Haematol. 2014;165:529\u201333. https:\/\/doi.org\/10.1111\/bjh.12735.","journal-title":"Br J Haematol"},{"key":"1285_CR33","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/CANCERS14030697","volume":"14","author":"D Oscier","year":"2022","unstructured":"Oscier D, Stamatopoulos K, Mirandari A, Strefford J. The genomics of hairy cell leukaemia and splenic diffuse red pulp lymphoma. Cancers. 2022;14:697. https:\/\/doi.org\/10.3390\/CANCERS14030697. An interesting review on the recent findings in genetics and epigenetics of HCL and SDRPL.","journal-title":"Cancers"},{"key":"1285_CR34","doi-asserted-by":"publisher","first-page":"28866","DOI":"10.18632\/oncotarget.25601","volume":"9","author":"E Maitre","year":"2018","unstructured":"Maitre E, Bertrand P, Maingonnat C, Viailly P-J, Wiber M, Naguib D, et al. New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. Oncotarget. 2018;9:28866\u201376. https:\/\/doi.org\/10.18632\/oncotarget.25601.","journal-title":"Oncotarget"},{"key":"1285_CR35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2015-04-643361","volume":"126","author":"S Dietrich","year":"2015","unstructured":"Dietrich S, Hullein J, Lee SC-W, Hutter B, Gonzalez D, Jayne S, et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015;126:1005\u20138. https:\/\/doi.org\/10.1182\/blood-2015-04-643361.","journal-title":"Blood"},{"key":"1285_CR36","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/sj.leu.2401721","volume":"14","author":"EA K\u00f6nig","year":"2000","unstructured":"K\u00f6nig EA, Kusser WC, Day C, Porzsolt F, Glickman BW, Messer G, et al. p53 mutations in hairy cell leukemia. Leukemia. 2000;14:706\u201311.","journal-title":"Leukemia"},{"key":"1285_CR37","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","volume":"114","author":"E Arons","year":"2009","unstructured":"Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687\u201395. https:\/\/doi.org\/10.1182\/blood-2009-01-201731.","journal-title":"Blood"},{"key":"1285_CR38","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood-2016-07-418434","volume":"128","author":"B Falini","year":"2016","unstructured":"Falini B, Martelli MP, Tiacci E. BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood. 2016;128:1918\u201327. https:\/\/doi.org\/10.1182\/blood-2016-07-418434.","journal-title":"Blood"},{"key":"1285_CR39","doi-asserted-by":"publisher","unstructured":"Tiacci E, Schiavoni G, Martelli MP, Boveri E, Pacini R, Tabarrini A, et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica. 2013;98. https:\/\/doi.org\/10.3324\/haematol.2012.078071.","DOI":"10.3324\/haematol.2012.078071"},{"key":"1285_CR40","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2014-10-603100","volume":"125","author":"V Pettirossi","year":"2015","unstructured":"Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood. 2015;125:1207\u201316. https:\/\/doi.org\/10.1182\/blood-2014-10-603100.","journal-title":"Blood"},{"key":"1285_CR41","doi-asserted-by":"publisher","unstructured":"Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34. https:\/\/doi.org\/10.1016\/j.it.2013.07.002.","DOI":"10.1016\/j.it.2013.07.002"},{"key":"1285_CR42","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1182\/BLOOD-2008-07-170415","volume":"113","author":"JA Burger","year":"2009","unstructured":"Burger JA, Quiroga MP, Hartmann E, B\u00fcrkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113:3050\u20138. https:\/\/doi.org\/10.1182\/BLOOD-2008-07-170415.","journal-title":"Blood"},{"key":"1285_CR43","doi-asserted-by":"publisher","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369. https:\/\/doi.org\/10.1056\/NEJMoa1306220.","DOI":"10.1056\/NEJMoa1306220"},{"key":"1285_CR44","doi-asserted-by":"publisher","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia. N Engl J Med. 2015;372. https:\/\/doi.org\/10.1056\/NEJMoa1501548.","DOI":"10.1056\/NEJMoa1501548"},{"key":"1285_CR45","doi-asserted-by":"publisher","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21. https:\/\/doi.org\/10.1038\/nm.3884.","DOI":"10.1038\/nm.3884"},{"key":"1285_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.beha.2015.09.006","volume":"28","author":"M Sivina","year":"2015","unstructured":"Sivina M, Burger JA. The importance of the tissue microenvironment in hairy cell leukemia. Best Pract Res Clin Haematol. 2015;28:208\u201316. https:\/\/doi.org\/10.1016\/j.beha.2015.09.006. It is a major review giving all the details about tumor microenvironment, chemokine receptors, and adhesion molecules in HCL.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1285_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjh.12867","volume":"166","author":"M Sivina","year":"2014","unstructured":"Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014;166:177\u201388. https:\/\/doi.org\/10.1111\/bjh.12867.","journal-title":"Br J Haematol"},{"key":"1285_CR48","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/BLOOD-2011-11-390989","volume":"119","author":"MFM De Rooij","year":"2012","unstructured":"De Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590\u20134. https:\/\/doi.org\/10.1182\/BLOOD-2011-11-390989.","journal-title":"Blood"},{"key":"1285_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/J.IMMUNI.2006.11.012","volume":"26","author":"DJJ de Gorter","year":"2007","unstructured":"de Gorter DJJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, et al. Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93\u2013104. https:\/\/doi.org\/10.1016\/J.IMMUNI.2006.11.012.","journal-title":"Immunity"},{"key":"1285_CR50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1888","volume":"6","author":"E Tiacci","year":"2006","unstructured":"Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer. 2006;6:437\u201348. https:\/\/doi.org\/10.1038\/nrc1888.","journal-title":"Nat Rev Cancer"},{"key":"1285_CR51","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1080\/10428190410001723449","volume":"45","author":"SWJ Wong","year":"2004","unstructured":"Wong SWJ, Fulcher DA. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma. 2004;45:2491\u20136. https:\/\/doi.org\/10.1080\/10428190410001723449.","journal-title":"Leuk Lymphoma"},{"key":"1285_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1084\/JEM.20031175","volume":"199","author":"K Basso","year":"2004","unstructured":"Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199:59\u201368. https:\/\/doi.org\/10.1084\/JEM.20031175.","journal-title":"J Exp Med"},{"key":"1285_CR53","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/sj.leu.2402107","volume":"15","author":"J D\u00fcrig","year":"2001","unstructured":"D\u00fcrig J, Schm\u00fccker U, D\u00fchrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia. 2001;15:752\u20136. https:\/\/doi.org\/10.1038\/sj.leu.2402107.","journal-title":"Leukemia"},{"key":"1285_CR54","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1182\/BLOOD.V88.10.3945.BLOODJOURNAL88103945","volume":"88","author":"AM Vincent","year":"1996","unstructured":"Vincent AM, Burthem J, Brew R, Cawley JC. Endothelial Interactions of hairy cells: the importance of \u03b14\u03b21 in the unusual tissue distribution of the disorder. Blood. 1996;88:3945\u201352. https:\/\/doi.org\/10.1182\/BLOOD.V88.10.3945.BLOODJOURNAL88103945.","journal-title":"Blood"},{"key":"1285_CR55","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1182\/BLOOD.V84.3.873.873","volume":"84","author":"J Burthem","year":"1994","unstructured":"Burthem J, Baker PK, Hunt JA, Cawley JC. Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell\u2019s response to specific adhesive proteins. Blood. 1994;84:873\u201382. https:\/\/doi.org\/10.1182\/BLOOD.V84.3.873.873.","journal-title":"Blood"},{"key":"1285_CR56","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/BLOOD.V118.21.1760.1760","volume":"118","author":"M Sivina","year":"2011","unstructured":"Sivina M, Kreitman RJ, Peled A, Ravandi F, Burger JA. Adhesion of hairy cells leukemia (HCL) Cells to stromal cells can be inhibited by blocking VLA-4 integrins and CXCR4 chemokine receptors. Blood. 2011;118:1760\u20131760. https:\/\/doi.org\/10.1182\/BLOOD.V118.21.1760.1760.","journal-title":"Blood"},{"key":"1285_CR57","doi-asserted-by":"publisher","unstructured":"Jain P, Pemmaraju N, Ravandi F. Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol. 2014;15. https:\/\/doi.org\/10.1007\/s11864-014-0285-5.","DOI":"10.1007\/s11864-014-0285-5"},{"key":"1285_CR58","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/blood-2002-12-3737","volume":"102","author":"KA Aziz","year":"2003","unstructured":"Aziz KA, Till KJ, Chen H, Slupsky JR, Campbell F, Cawley JC, et al. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL). Blood. 2003;102:1051\u20136. https:\/\/doi.org\/10.1182\/blood-2002-12-3737.","journal-title":"Blood"},{"key":"1285_CR59","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1182\/BLOOD.V96.9.3161","volume":"96","author":"KA Aziz","year":"2000","unstructured":"Aziz KA, Till KJ, Zuzel M, Cawley JC. Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood. 2000;96:3161\u20137. https:\/\/doi.org\/10.1182\/BLOOD.V96.9.3161.","journal-title":"Blood"},{"key":"1285_CR60","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1172\/JCI19540","volume":"113","author":"M Shehata","year":"2004","unstructured":"Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest. 2004;113:676\u201385. https:\/\/doi.org\/10.1172\/JCI19540.","journal-title":"J Clin Invest"},{"key":"1285_CR61","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/BLOOD.V83.2.497.497","volume":"83","author":"J Burthem","year":"1994","unstructured":"Burthem J, Cawley J. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood. 1994;83:497\u2013504. https:\/\/doi.org\/10.1182\/BLOOD.V83.2.497.497.","journal-title":"Blood"},{"key":"1285_CR62","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00277-014-2140-y","volume":"93","author":"E Cornet","year":"2014","unstructured":"Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, et al. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol. 2014;93:1977\u201383. https:\/\/doi.org\/10.1007\/s00277-014-2140-y.","journal-title":"Ann Hematol"},{"key":"1285_CR63","unstructured":"Sundar H, Fletcher CD, Gaballa S, Ghobadi A, \u03be \u00de, Saad Hamid M, et al. NCCN guidelines version 1.2022 hairy cell leukemia continue NCCN guidelines panel disclosures. 2021. These are the latest recommendations of the NCCN for the treatment of HCL and HCL-V."},{"key":"1285_CR64","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/10428199909169620","volume":"35","author":"JN Bastie","year":"1999","unstructured":"Bastie JN, Cazals-Hatem D, Daniel MT, D\u2019agay MF, Rabian C, Glaisner S, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma. 1999;35:555\u201365. https:\/\/doi.org\/10.1080\/10428199909169620.","journal-title":"Leuk Lymphoma"},{"key":"1285_CR65","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4274\/tjh.2016.0443","volume":"34","author":"\u015e \u00d6ng\u00f6ren","year":"2017","unstructured":"\u00d6ng\u00f6ren \u015e, E\u015fkazan AE, Berk S, Elverdi T, Saliho\u011flu A, Ar MC, et al. Retrospective evaluation of hairy cell leukemia patients treated with three different first-line treatment modalities in the last two decades: a single-center experience. Turk J Hematol. 2017;34:291\u20139. https:\/\/doi.org\/10.4274\/tjh.2016.0443.","journal-title":"Turk J Hematol"},{"key":"1285_CR66","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/sj.leu.2403418","volume":"18","author":"U Jehn","year":"2004","unstructured":"Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18:1476\u201381. https:\/\/doi.org\/10.1038\/sj.leu.2403418.","journal-title":"Leukemia"},{"key":"1285_CR67","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.clml.2017.07.003","volume":"17","author":"YF Madanat","year":"2017","unstructured":"Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, et al. Long-term outcomes of hairy cell leukemia treated with purine analogs: a comparison with the general population. Clin Lymphoma Myeloma Leuk. 2017;17:857\u201362. https:\/\/doi.org\/10.1016\/j.clml.2017.07.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1285_CR68","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3109\/10428194.2013.827187","volume":"55","author":"M L\u00f3pez Rubio","year":"2014","unstructured":"L\u00f3pez Rubio M, Da Silva C, Loscertales J, Seri C, Baltasar P, Colado E, et al. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leuk Lymphoma. 2014;55:1007\u201312. https:\/\/doi.org\/10.3109\/10428194.2013.827187.","journal-title":"Leuk Lymphoma"},{"key":"1285_CR69","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hon.2177","volume":"33","author":"S Hacioglu","year":"2015","unstructured":"Hacioglu S, Bilen Y, Eser A, Sivgin S, Gurkan E, Yildirim R, et al. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy. Hematol Oncol. 2015;33:192\u20138. https:\/\/doi.org\/10.1002\/hon.2177.","journal-title":"Hematol Oncol"},{"key":"1285_CR70","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","volume":"145","author":"M Else","year":"2009","unstructured":"Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZS, Johnson SAN, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733\u201340. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07668.x.","journal-title":"Br J Haematol"},{"key":"1285_CR71","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1002\/cncr.25243","volume":"116","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer. 2010;116:4788\u201392. https:\/\/doi.org\/10.1002\/cncr.25243.","journal-title":"Cancer"},{"key":"1285_CR72","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood-2013-06-508754","volume":"123","author":"JD Rosenberg","year":"2014","unstructured":"Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014;123:177\u201383. https:\/\/doi.org\/10.1182\/blood-2013-06-508754.","journal-title":"Blood"},{"key":"1285_CR73","first-page":"32","volume":"27","author":"JB Johnston","year":"2000","unstructured":"Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol. 2000;27:32\u20136.","journal-title":"Semin Oncol"},{"key":"1285_CR74","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjh.14207","volume":"175","author":"BM Getta","year":"2016","unstructured":"Getta BM, Woo KM, Devlin S, Park JH, Abdel-Wahab O, Saven A, et al. Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. Br J Haematol. 2016;175:402\u20139. https:\/\/doi.org\/10.1111\/bjh.14207.","journal-title":"Br J Haematol"},{"key":"1285_CR75","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.leu.2402784","volume":"17","author":"F Maloisel","year":"2003","unstructured":"Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003;17:45\u201351. https:\/\/doi.org\/10.1038\/sj.leu.2402784.","journal-title":"Leukemia"},{"key":"1285_CR76","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","volume":"21","author":"GR Goodman","year":"2003","unstructured":"Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891\u20136. https:\/\/doi.org\/10.1200\/JCO.2003.05.093.","journal-title":"J Clin Oncol"},{"key":"1285_CR77","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1182\/blood.V96.1.71","volume":"96","author":"IW Flinn","year":"2000","unstructured":"Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000;96:2981\u20136.","journal-title":"Blood"},{"key":"1285_CR78","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","volume":"92","author":"A Saven","year":"1998","unstructured":"Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918\u201326.","journal-title":"Blood"},{"key":"1285_CR79","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.14129","volume":"174","author":"D Chihara","year":"2016","unstructured":"Chihara D, Kantarjian H, O\u2019Brien S, Jorgensen J, Pierce S, Faderl S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174:760\u20136. https:\/\/doi.org\/10.1111\/bjh.14129.","journal-title":"Br J Haematol"},{"key":"1285_CR80","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.19.02250","volume":"38","author":"D Chihara","year":"2020","unstructured":"Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020;38:1527. https:\/\/doi.org\/10.1200\/JCO.19.02250. This study compares the combination of cladribine + R in a concurrent schedule versus a sequential schedule in HCL.","journal-title":"J Clin Oncol"},{"key":"1285_CR81","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2021005039","author":"D Chihara","year":"2021","unstructured":"Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang H-W, Zhou H, et al. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2021005039. This recently published phase II study shows good results of the combination cladribine + R in HCL-V.","journal-title":"Blood Adv"},{"key":"1285_CR82","doi-asserted-by":"publisher","first-page":"E180","DOI":"10.1002\/ajh.25474","volume":"94","author":"J-P Bohn","year":"2019","unstructured":"Bohn J-P, Pircher A, Wanner D, Vill D, Foeger B, Wolf D, et al. Low-dose vemurafenib in hairy cell leukemia patients with active infection. Am J Hematol. 2019;94:E180\u20132. https:\/\/doi.org\/10.1002\/ajh.25474.","journal-title":"Am J Hematol"},{"key":"1285_CR83","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1600-0609.2009.01259.x","volume":"83","author":"G Damaj","year":"2009","unstructured":"Damaj G, Kuhnowski F, Marolleau J-P, Bauters F, Leleu X, Yakoub-Agha I. Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol. 2009;83:246\u201350. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01259.x.","journal-title":"Eur J Haematol"},{"key":"1285_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5616898","volume":"2018","author":"JC Barton","year":"2018","unstructured":"Barton JC, Edmunds HS. Listeria monocytogenes infection in hairy cell leukemia: a case report and literature review. Case Rep Hematol. 2018;2018:1\u20135. https:\/\/doi.org\/10.1155\/2018\/5616898.","journal-title":"Case Rep Hematol"},{"key":"1285_CR85","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1182\/blood.V92.4.1160","volume":"92","author":"WY Au","year":"1998","unstructured":"Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood. 1998;92:1160\u20134.","journal-title":"Blood"},{"key":"1285_CR86","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2021013502","author":"B Falini","year":"2022","unstructured":"Falini B, De Carolis L, Tiacci E. How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors. Blood. 2022. https:\/\/doi.org\/10.1182\/BLOOD.2021013502.","journal-title":"Blood"},{"key":"1285_CR87","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","volume":"373","author":"E Tiacci","year":"2015","unstructured":"Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1506583. This is the major article demonstrating the efficacy of vemurafenib in R\/R HCL.","journal-title":"N Engl J Med"},{"key":"1285_CR88","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/BLOOD.V130.SUPPL_1.156.156","volume":"130","author":"X Troussard","year":"2017","unstructured":"Troussard X, Montan\u00e9 L, Tiab M, Chaleteix C, Grulois I, Lindet C, et al. Vemurafenib in advanced patients with hairy cell leukemia (HCL): results of the Acs\u00e9 Phase II Trial. Blood. 2017;130:156\u2013156. https:\/\/doi.org\/10.1182\/BLOOD.V130.SUPPL_1.156.156.","journal-title":"Blood"},{"key":"1285_CR89","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","volume":"127","author":"S Dietrich","year":"2016","unstructured":"Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner C-M, Follows GA, et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood. 2016;127:2847\u201355. https:\/\/doi.org\/10.1182\/blood-2015-11-680074.","journal-title":"Blood"},{"key":"1285_CR90","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/S41375-021-01210-8","volume":"35","author":"E Tiacci","year":"2021","unstructured":"Tiacci E, De Carolis L, Simonetti E, Merluzzi M, Bennati A, Perriello VM, et al. Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial. Leukemia. 2021;35:3314\u20138. https:\/\/doi.org\/10.1038\/S41375-021-01210-8.","journal-title":"Leukemia"},{"key":"1285_CR91","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood-2018-99-113135","volume":"132","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Moreau P, Hutchings M, Gazzah A, Blay J-Y, Wainberg ZA, et al. Treatment with combination of dabrafenib and trametinib in patients with recurrent\/refractory BRAF V600E-mutated hairy cell leukemia (HCL). Blood. 2018;132:391\u2013391. https:\/\/doi.org\/10.1182\/blood-2018-99-113135. An article showing good results with the combination of a BRAFi (dabrafenib) and a MEKi (trametinib) in R\/R HCL.","journal-title":"Blood"},{"key":"1285_CR92","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/nejmoa2031298","volume":"384","author":"E Tiacci","year":"2021","unstructured":"Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, et al. Vemurafenib plus Rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021;384:1810\u201323. https:\/\/doi.org\/10.1056\/nejmoa2031298. This study demonstrates the great efficacy of the combination of vemurafenib + R in R\/R HCL, with uMRD and prolonged DOR.","journal-title":"N Engl J Med"},{"key":"1285_CR93","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/ajh.24936","volume":"92","author":"X Troussard","year":"2017","unstructured":"Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2017;92:1382\u201390. https:\/\/doi.org\/10.1002\/ajh.24936.","journal-title":"Am J Hematol"},{"key":"1285_CR94","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1182\/bloodadvances.2019000507","volume":"3","author":"AY Lin","year":"2019","unstructured":"Lin AY, Dinner SN. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval. Blood Adv. 2019;3:2905\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2019000507.","journal-title":"Blood Adv"},{"key":"1285_CR95","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","volume":"30","author":"RJ Kreitman","year":"2012","unstructured":"Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30:1822\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.38.1756.","journal-title":"J Clin Oncol"},{"key":"1285_CR96","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","volume":"32","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, et al. Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia. Leukemia. 2018;32:1768\u201377. https:\/\/doi.org\/10.1038\/s41375-018-0210-1.","journal-title":"Leukemia"},{"key":"1285_CR97","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","volume":"131","author":"RJ Kreitman","year":"2018","unstructured":"Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131:2331\u20134. https:\/\/doi.org\/10.1182\/blood-2017-09-803072.","journal-title":"Blood"},{"key":"1285_CR98","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","volume":"14","author":"RJ Kreitman","year":"2020","unstructured":"Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Robak T, Le Coutre PD, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2020;14:35. https:\/\/doi.org\/10.1186\/s13045-020-01004-y. This article presents the updated results of the study showing promising efficacy of Moxe, an anti-CD22 immunoconjugate, in R\/R HCL, with uMRD and a good tolerance.","journal-title":"J Hematol Oncol"},{"key":"1285_CR99","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/blood.2020009688","volume":"137","author":"KA Rogers","year":"2021","unstructured":"Rogers KA, Andritsos LA, Wei L, McLaughlin EM, Ruppert AS, Anghelina M, et al. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood. 2021;137:3473\u201383. https:\/\/doi.org\/10.1182\/blood.2020009688. This phase II study demonstrates the efficacy of ibrutinib, a BTKi, in R\/R HCL and HCL-V.","journal-title":"Blood"},{"key":"1285_CR100","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1080\/10428194.2016.1239262","volume":"58","author":"J-P Bohn","year":"2017","unstructured":"Bohn J-P, Wanner D, Steurer M. Ibrutinib for relapsed refractory hairy cell leukemia variant. Leuk Lymphoma. 2017;58:1224\u20136. https:\/\/doi.org\/10.1080\/10428194.2016.1239262.","journal-title":"Leuk Lymphoma"},{"key":"1285_CR101","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/HON.2810","volume":"38","author":"A Visentin","year":"2020","unstructured":"Visentin A, Imbergamo S, Trimarco V, Pravato S, Romano Gargarella L, Frezzato F, et al. Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature. Hematol Oncol. 2020;38:823\u20136. https:\/\/doi.org\/10.1002\/HON.2810.","journal-title":"Hematol Oncol"},{"key":"1285_CR102","doi-asserted-by":"publisher","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374. https:\/\/doi.org\/10.1056\/NEJMoa1513257.","DOI":"10.1056\/NEJMoa1513257"},{"key":"1285_CR103","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.3389\/FONC.2021.598319\/BIBTEX","volume":"11","author":"A Vereertbrugghen","year":"2021","unstructured":"Vereertbrugghen A, Colado A, Gargiulo E, Bezares RF, Fern\u00e1ndez Grecco H, Cordini G, et al. In vitro sensitivity to venetoclax and microenvironment protection in hairy cell leukemia. Front Oncol. 2021;11:2595. https:\/\/doi.org\/10.3389\/FONC.2021.598319\/BIBTEX.","journal-title":"Front Oncol"},{"key":"1285_CR104","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/AJH.25264","volume":"93","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Konoplev S, Zuo Z, Estrov Z. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax. Am J Hematol. 2018;93:1568\u20139. https:\/\/doi.org\/10.1002\/AJH.25264.","journal-title":"Am J Hematol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01285-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:11:18Z","timestamp":1663027878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01285-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01285-1","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"21 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to Reproduce Material from Other Sources"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Registration"}},{"value":"Xavier Troussard. Consultant for Innate Pharma, Astra Zeneca, Abbvie, Beigne. J\u00e9r\u00f4me Paillassa et Elsa Maitre. The authors declare no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}